PINK1/Parkin pathway-mediated mitophagy by AS-IV to explore the molecular mechanism of muscle cell damage
Source : https://www.sciencedirect.com/science/article/pii/S0753332223003219?via=ihub
The combination of CCCP and H 2O 2 can induce excessive mitophagy. * AS-IV can reduce excessive mitophagy through the PINK1/Parkin pathway. * AS-IV can improve L6 cells damage and...
Conclusion: AS-IV is a potential drug for myasthenia gravis (MG), and its treatment mechanism is related to mediating mitophagy and restoring mitochondrial function through the PINK1/Parkin pathway.
Effects of comorbid diseases on clinical outcomes in patients with myasthenia gravis - Neurological Sciences
Source : https://link.springer.com/article/10.1007/s10072-023-06750-8
Background This cross-sectional study was undertaken to evaluate the existence and distribution of comorbid disorders among myasthenia gravis (MG) patients according to subgroups and to identify the effects of the...
Conclusion: Hypertension and type 2 DM had negative effects on the clinical outcomes of MG.
Impact of dysautonomic symptom burden on the quality of life in Neuromyelitis optica spectrum disorder patients - BMC Neurology
Source : https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-023-03162-1
Background This study aimed to investigate the clinical risk factors of dysautonomic symptom burden in neuromyelitis optica spectrum disorder (NMOSD) and its impact on patients' quality of life. Methods A...
Conclusions: Dysautonomic symptom burden is correlated with decreased quality of life and certain clinical characteristics such as disability, the burden of spinal cord lesions, and fatigue in NMOSD patients. Investigation and proper management of autonomic dysfunction may help to improve the quality of life in patients with NMOSD.
Caution on LRP4 antibody results in patients being evaluated for myasthenia gravis
Source : https://www.jni-journal.com/article/S0165-5728(23)00049-8/fulltext
We read with interest the article titled, "LRP4-IgG service line testing in seronegative myasthenia gravis and controls" (Klein et al., 2022). The publication described results of low density lipoprotein receptor-related...
Conclusions/Relevance: Caution is needed in diagnosing myasthenia gravis based on LRP4 antibody positivity alone.
Intravenous immunoglobulin (Gamunex® 10%) is licensed for the treatment of severe acute exacerbations of myasthenia gravis
Source : https://www.tandfonline.com/doi/full/10.1080/14656566.2023.2192867
Dear Editor, In a recent Editorial published in Expert Opinion on Pharmacotherapy, Vanoli and Mantegazza [1] discussed current therapeutics for myasthenia gravis (MG).
Conclusions/Relevance: We believe that it is important for clinicians to have accurate information on the availability of approved therapies. In this case, that IVIg is, in fact, licensed for the treatment of MG exacerbations.